Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Sweden / NCT04433364
Active, not recruiting Observational

COPE - COVID-19 in Pregnancy and Early Childhood

NCT04433364 · tracked via the Priya Life Science Sweden tracker
Phase
Observational
Started
2020-06-02
Last updated
2024-04-16

Condition(s) studied

Sars-CoV2Covid-19Pregnancy ComplicationsPregnancy PretermPregnancy in DiabeticNeonatal Infection

Investigational drug(s) / intervention(s)

biological samples, questionnaires and interviews

biological samples, questionnaires and interviews: Biological samples: to study impact of testing positive for SARS-CoV-2 during pregnancy samples taken in routine clinical care, samples from already existing research biobanks and the newly established COPE biobank will be used. Time-points: inclusion, at delivery mother and fetus. Covid-19 positive group only: 48-96 h, 2 months postpartum for mother and fetus. Questionnaires: Women and partners in both groups will fill out electronical questionnaires at different time points during pregnancy and until 12 months postpartum based on validated instruments to test for differences in Self-Efficacy, Anxiety and Depression, Health-related quality of life, Sense of Coherence, PTSD Symptoms, Postpartum Bonding, Childbirth experiences and Self-Efficacy of Breastfeeding. The child's health will be assessed regarding infection until 6 weeks of age and development until 4 years. Interviews: 24-40 women and partners in both groups. Interviews will be conducted 3 to 6 months after childbirth.

Study summary

Purpose: The emergence of a new coronavirus SARS-CoV-2 causing a novel infection in the human race resulting in a world-spanning pandemic came as a surprise and at a tremendous cost both for individual human lives as well as for the society and the health care sector. The knowledge on how this new infection affects both the mother and the unborn child as well as the outcomes for the mother and the child in the long run are unknown. What is known is based on case-reports and small case-series solely. Both the coronaviruses causing Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS) can cause a threat to pregnant women and their offspring, which leads to the question whether this could be the case also for SARS-CoV-2.

Aims: To establish a biobank of biological material from infected as well as non-infected pregnant women and their offspring. To combine this biobank with Swedish quality and health care registers, computerized patient charts and questionnaire data, enabling both short-term follow up, such as obstetric outcomes, as well as long-term outcomes both for mother and child. To study how the pandemic situation affects both the mother and her partner in their experience of pregnancy, childbirth, and early parenthood.

Design: A national Swedish multicentre study. Women are included when they have a positive test for SARS-CoV-2 or a clinical suspicion of coronavirus disease 2019 (COVID-19) (COVID-19 group). Pregnant women without COVID-19 symptoms will be included at their routine visits (Screening group). Blood samples and other biological material will be collected at different time-points. Additional predictors and outcomes are collected from the Swedish Pregnancy Register as well as obligatory Swedish health registers. The biobank and its linkage to health registers through the Swedish personal identification number will enable future research. Child development will be followed during the first year of life by questionnaires to the parents. Womens' and their partners' experience of childbirth and parenthood will be studied in form of questionnaires as well as in form of interviews.

Conclusion: This project will help obstetricians and neonatologists better recognize clinical manifestations of the virus, identify possible risk factors during pregnancy and tailor therapies alongside providing right level of surveillance and management during pregnancy, delivery, and child health care.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Pregnant women 18 years of age and above * Attending routine antenatal visits at a participating hospital during the study period or are strongly suspicious of or diagnosed with Covid-19 during pregnancy. * For the questionnaire part: language knowledge (Swedish, English, Arabic, Somali) * For the interview part: Swedish language knowledge Exclusion Criteria: • Another language but selected ones

Primary outcome measure(s)

Trial sites (27)

FacilityCityRegionStatus
Falu Hospital Falun Dalarna County
Halmstad lasarett Halmstad Halland County
Varbergs sjukhus Varberg Halland County
Helsingborgs lasarett Helsingborg Skåne County
Skåne Universitetssjukhus Lund Skåne County
Eskiltuna hospital Eskilstuna Södermanland County
Boras hospital Borås VGR
Sahlgrenska Univeristy Hospital Gothenburg VGR
Ryhovs sjukhus Jönköping Sweden
Kalmar Lasarett Kalmar Sweden
Karlstad lasarett Karlstad Sweden
Kristiandstad länssjukhus Kristianstad Sweden
Örebro University Hospital Örebro Sweden
Skaraborgs sjukhus Skövde Skövde Sweden
BB Stockholm Stockholm Sweden
Danderyd Stockholm Sweden
Karolinska University Hospital Solna Stockholm Sweden
Karolinska University Hospital- Huddinge Stockholm Sweden
Södersjukhuset Stockholm Sweden
Södertälje Stockholm Sweden
Sundsvall Sundsvall Sweden
Umeå University Hospital Umeå Sweden
Uppsala University Hospital Uppsala Sweden
Västerås Västerås Sweden
Ystad Ystad Sweden
Linköping University Hospital Linköping Östergötland County
Vrinnevisjukhuset Norrköping Östergötland County

More Sahlgrenska University Hospital trials in Sweden

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04433364 on ClinicalTrials.gov ↗ ← All trials in Sweden